REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-18. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Chief Operating Officer Scott Boatwright was appointed by the board as interim CEO effective August 31, 2024. At the same board meeting, company director Scott Maw was named chairman of the board and retiring CFO Jack Hartung was named president. Four months later, Boatwright was named permanent CEO by the board in November 2024. Chipotle's key management as of January 2026 consists of:
== Medicine == Muscle contraction, the physiological condition of a muscle which generates tension (traction) at its origin and insertion Uterine contraction, contraction of the uterus, such as during childbirth Contractility, the intrinsic ability of the heart/myocardium to contract Wound contraction, a stage in wound healing
Vice writer Patrick Klepek felt that the Headcrab was an iconic enemy known by people outside the Half-Life fandom, stating that due to it becoming more familiar, it became less intimidating, citing the fact that it was made into a plush. He felt that the Headcrabs in Half-Life: Alyx were responsible for making Headcrabs scary again, stating that it being a virtual reality game made its attacks that much more frightening. He felt that the Headcrabs being scary served as proof of how well Alyx works as a video game. Dread Central writer Justin Wood felt similarly about the virtual reality technology, stating that the sight of Headcrabs jumping at the player created "visceral reactions", as well as making him uncomfortable to hear them creeping around. Kotaku writer Nathan Grayson stated that, through his time playing Alyx, he had never gotten used to the "nauseating sense of dread" from the fear of being attacked by Headcrabs. He felt that this went beyond just being in virtual reality, praising the development team for managing to create such good sound design and animation that being accosted by Headcrabs inspired genuine fear in him. Twitch producer Mary Kish regarded Alyx as one of her favorite video games of 2020, stating that it being "genuinely scary" was a large part of why she liked it. She discussed how the Headcrabs function in it, which caused her to hold her breath in response to a Headcrab's presence, believing they pulled off a sense of danger well.
=== Chronic === Assessment of the effects of stimulants is relevant given the large population currently taking stimulants. A 2022 meta-analysis with a sample size of just under four million people found no association between the use of prescription stimulants and the development of cardiovascular disease in any age group. A review of a year long period of prescription stimulant use in those with attention deficit hyperactivity disorder (ADHD) found that cardiovascular side effects were limited to transient increases in blood pressure only. However, a 2024 systematic review of the evidence found that stimulants overall improve ADHD symptoms and broadband behavioral measures in children and adolescents, though they carry risks of side effects like appetite suppression and other adverse events. Initiation of stimulant treatment in those with ADHD in early childhood appears to carry benefits into adulthood in social and cognitive functioning, and appears to be relatively safe. Abuse of prescription stimulants (not following physician instruction) or of illicit stimulants carries many negative health risks. Abuse of cocaine, depending upon route of administration, increases risk of cardiorespiratory disease, stroke, and sepsis.
Sources: en.wikipedia.org
=== Diabetes and obesity === Lacking anti-inflammatory dermal macrophages in diabetic patients results in impaired wound healing ability. Dermal macrophages are arrested at the pro-inflammatory phenotype, which increases the difficulty in the healing process due to their production of pro-inflammatory cytokines. Ulcers on foot are common in a patient with severe diabetes due to the prolonged impairment of wound healing. Pro-inflammatory (M1) macrophages are also frequently observed in obese individuals' subcutaneous tissues. This is related to the progression of diabetes with chronic adipose tissue inflammation. However, the explicit roles of dermal macrophages in obesity are still unclear.
== Death == On February 21, 1961, Jones died of lung cancer at age 67 in Minneapolis, Minnesota, predeceasing his wife, Lucille. In an obituary in the Saturday Evening Post, it was said, "Most engineers start at the bottom of a project and work up, but Fred takes a flying leap to the top of the mountain and then backs down, cutting steps for himself and the rest of us as he goes." Jones continued filing for patents almost up until his death, receiving his last patent in February 1960.
The production was held at the Eugene O'Neill Theatre in New York City to raise money for the American Foundation for Equal Rights. Freeman had a lead role in the 2012 drama The Magic of Belle Isle, as an alcoholic novelist trying to write again. The film fared poorly with critics, gaining only a 29% approval rating on Rotten Tomatoes. Lastly in 2012, Freeman reprised his role as Lucius Fox for the third time in The Dark Knight Rises. A number of box office hits were released in 2013. Freeman appeared in the action-thriller Olympus Has Fallen, the first installment in what would become the Has Fallen film series; he portrays Speaker of the House Allan Trumbull. The San Francisco Chronicle critic gave Olympus Has Fallen 3 out of 4 stars and opined that Freeman gave an amicable supporting performance. He then starred in the science fiction drama Oblivion, with co-star Tom Cruise, as veteran soldier Malcolm Beech, and appeared in the thriller Now You See Me, as an ex-magician. Lastly, he played a retiree in Last Vegas, with co-stars Michael Douglas, Robert De Niro, Kevin Kline, and Mary Steenburgen. Filmed in Las Vegas and Atlanta, Last Vegas was praised for its cast's chemistry, and one critic thought Freeman brought the most amusement. In 2014, Freeman voiced the character Vitruvius in The Lego Movie, a commercially successful 3D animation. He starred in Transcendence, a science fiction thriller directed by Wally Pfister in his directorial debut, in which Freeman plays scientist Joseph Tagger. Critic reviews of the film were generally mixed, according to Metacritic.
Sources: en.wikipedia.org
==== United States ==== 4-HO-EPT may be considered an analogue of psilocin, which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption would be illegal under the Federal Analogue Act.
=== Psychological factors === Two psychological processes appear to be involved in regulating short-term food intake: liking and wanting. Liking refers to the palatability or taste of the food, which is reduced by repeated consumption. Wanting is the motivation to consume the food, which is also reduced by repeated consumption of a food and may be due to change in memory-related processes. Wanting can be triggered by a variety of psychological processes. Thoughts of a food may intrude on consciousness and be elaborated on, for instance, as when one sees a commercial or smells a desirable food.
== Mechanism == Silanization mechanisms vary with substrate and with silanization reagent. In the usual circumstance, surface MOH groups react as nucleophiles with silyl chlorides or silyl alkoxides. The stoichiometry for these reactions are shown:
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.